Using MC1R Genotype to Impact Melanoma Risk Behavior



Status:Active, not recruiting
Conditions:Skin Cancer, Skin Cancer, Cancer, Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/16/2019
Start Date:August 3, 2015
End Date:February 2021

Use our guide to learn which trials are right for you!

The purpose of this study is to examine how different messages about risk of melanoma can
impact the way people protect themselves against developing these diseases.


Inclusion Criteria:

CRITERIA FOR: NON-HISPANIC WHITE POPULATION - NOW RECRUITING

- Investigators will recruit participants from the Family Medicine and General Internal
Medicine clinics of the Morsani Center at the University of South Florida.

- White, non-Hispanic patients who self-report a low phenotypic risk profile for
development of melanoma and are able to read and speak English fluently.

- 18 years of age or older

- Capable of giving informed consent

- Potential participants will be screened for eligibility based on responses to
questions about skin phenotypes, early detection behaviors and past history of
melanoma.

- After signing informed consent, a biologic sample (saliva) will be collected for the
purpose of DNA extraction determination of MC1R genotypes. All participants who carry
high risk MC1R genotypes and a proportion of those who carry low risk or no MC1R
variants will be randomized to the control or intervention arm.

CRITERIA FOR: HISPANIC POPULATION - WILL BEGIN RECRUITING SOON

- Investigators will recruit participants living in Tampa Bay and Puerto Rico as part of
the U54 Ponce Health Sciences University-Moffitt Cancer Center (PHSU-MCC) Partnership.
In Tampa Bay, participants will be recruited from the Family Medicine and General
Internal Medicine clinics of the Morsani Center at the University of South Florida,
and from the Suncoast Community Health Centers.

- Patients who self-report as Hispanics and are able to read and speak either Spanish or
English fluently.

- 18 years of age or older

- Capable of giving informed consent

- Potential participants will be screened for eligibility based on responses to early
detection behaviors and past history of melanoma.

- After signing informed consent, a biologic sample (saliva) will be collected for the
purpose of DNA extraction determination of MC1R genotypes. All participants who carry
high risk MC1R genotypes and a proportion of those who carry low risk or no MC1R
variants will be randomized to the control or intervention arm.

Exclusion Criteria:

CRITERIA FOR: NON-HISPANIC WHITE POPULATION - NOW RECRUITING

- Have had a skin examination within the past year.

- Do not meet race/ethnicity criteria for their group

- White, non-Hispanic group - participants reporting sun-sensitive phenotypes

- A personal history of melanoma

CRITERIA FOR: HISPANIC POPULATION - WILL BEGIN RECRUITING SOON

- Have had a skin examination within the past year.

- Do not meet ethnicity criteria for their group

- White, non-Hispanic group - participants reporting sun-sensitive phenotypes

- Participants with a personal history of melanoma and/or more personal history of more
than on squamous cell cancer (SCC) and/or Basal Cell Cancer (BCC)
We found this trial at
1
site
12902 USF Magnolia Dr
Tampa, Florida 33612
(888) 663-3488
Principal Investigator: Peter Kanetsky, Ph.D.
Phone: 813-745-2853
H. Lee Moffitt Cancer Center & Research Institute Moffitt Cancer Center in Tampa, Florida, has...
?
mi
from
Tampa, FL
Click here to add this to my saved trials